Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma
Phase of Trial: Phase II
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Diffuse large B cell lymphoma; Hodgkin's disease
- Focus Therapeutic Use
- Acronyms JAK2
- 25 Oct 2017 Status changed from active, no longer recruiting to completed.
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 16 May 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.